MEGACE ES Rx
Generic Name and Formulations:
Megestrol acetate 125mg/mL; oral susp; lemon-lime flavor.
Par Pharmaceutical, Inc.
Indications for MEGACE ES:
Anorexia, cachexia, or unexplained significant weight loss in patients diagnosed with AIDS.
Limitations Of use:
Should only be instituted after treatable causes of weight loss are sought and addressed. Not for prophylactic use to avoid weight loss.
625mg/5mL per day.
Known or suspected pregnancy (Cat.X).
Do not substitute with other megestrol suspensions (not interchangeable). History of thromboembolic disease. Monitor for signs/symptoms of adrenal insufficiency; consider empiric therapy if occurs. Diabetes. Renal impairment. Elderly. Avoid in women of childbearing potential. Nursing mothers: not recommended.
May increase insulin requirements. Decreases indinavir levels.
Nausea, diarrhea, impotence, rash, flatulence, hypertension, asthenia; rare: adrenal insufficiency, breakthrough bleeding.
Concentrated susp (125mg/mL)—5oz
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Congress Passes Bill to Fight Opioid Crisis
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure